Reata reports retained benefit in Phase II CKD trial

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment.

In 25 patients with CKD due to Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial, once-daily oral bardoxolone significantly increased mean eGFR at week 48 by 10.4 mL/min/1.73 m² compared with baseline (p<0.0001). At week 52, four weeks after discontinuing treatment, bardoxolone continued to significantly improve eGFR compared with baseline (increase of 4.1 mL/min/1.73 m², p<0.05), which the company said provides evidence that the candidate may delay or prevent kidney failure...